P1SH
MHRCCGi001-A
General
Cell Line |
|
hPSCreg name | MHRCCGi001-A |
Cite as: | MHRCCGi001-A (RRID:CVCL_D0I7) |
Alternative name(s) |
P1SH
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
MHRCCGi004-A (A1SH) MHRCCGi005-A (A2SH) RCMGi011-A (P10L1) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 RCMGi011-B (P10L2) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 LUMCi027-A (LUMC0153iPKP03) Donor's gene variants: PKP2 Donor diseases: arrhythmogenic right ventricular dysplasia 9 |
Last update | 6th April 2023 |
User feedback | |
Provider |
|
Generator | Laboratory Clinical Genetics (MHRCCG) |
Owner | Laboratory Clinical Genetics (MHRCCG) |
Distributors | |
Derivation country | Russia |
External Databases |
|
BioSamples | SAMEA112366444 |
Cellosaurus | CVCL_D0I7 |
Wikidata | Q123033043 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Is the medical history available upon request? | The patient was followed up for more than 20 years. The medical history is available upon request. |
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
de novo variant in SLC6A1 was found |
Donor Relations |
|
All cell lines of this donor's relatives |
Has father:
Has mother:
|
External Databases (Donor) |
|
BioSamples | SAMEA112373099 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Has the donor agreed to be re-contacted? | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent permit unforeseen future research, without further consent? | Yes |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | No |
a non-profit company? | No |
a for-profit corporation? | No |
Does consent expressly permit collection of genetic information? | Yes |
Does consent expressly permit storage of genetic information? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Federal State Budgetary Scientific Institution Mental Health Research Centre Ethics Committee |
Approval number | 873 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type | |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Lentivirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
Yes |
Reprogramming vectors silenced? |
Yes |
Methods used |
Immunostaining, RT-PCR
|
Vector free reprogramming |
|
Other |
|
Selection criteria for clones | Analysis of the morphology of clones that maximally resemble ESCs |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
Accutase
|
Medium |
Other medium:
Base medium: StemFit™ Basic04CT (Complete Type)
Main protein source: Serum concentration: % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SSEA-4 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
SOX2 |
Yes |
|||||
TRA 1-81 |
Yes |
|||||
TRA 1-60 |
Yes |
Morphology pictures
iPS-SH-p 20x-3.tif
Colony morphology
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.